Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An open-label randomised phase III trial of 5-fluorocil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer.

Dates: Ongoing since 2007
Funding: Cancer Research UK
Collaborators: Radiology Oncology Biology Unit, University of Oxford
Information: Jane Wolstenholme

This is a Phase III randomized trial comparing the addition of liver-targeted brachytherapy (radioembolisation) to systemic chemotherapy compared with current standard treatment in patients with liver metastatic colorectal cancer.  HERC will undertake a cost-effectiveness analysis alongside this Phase III trial.  Detailed data on resource utilization associated with health care (primary and secondary care) and informal care are being collected alongside the trial.  Data on patient costs and change in employments status over the time-horizon of the trial are also being routinely documented.  Health-related quality of life is being routinely collected using the EORTC QLQ-C30/QLQ-LCM21 and the EQ-5D instruments.